欧洲疾控中心欧洲经济区的抗菌药物消费（ESACNet）2023年年度流行病学报告（英）

Investment Rating - The report does not explicitly provide an investment rating for the industry Core Insights - The report highlights the need for improved efforts to address antimicrobial consumption in the EU/EEA, as current trends show insufficient progress towards established targets [4][18] Summary by Relevant Sections Antimicrobial Consumption Overview - In 2023, the EU population-weighted mean total consumption of antibacterials for systemic use was 20.0 DDD per 1,000 inhabitants per day, which is 1% higher than in 2019 [25] - The range of total antimicrobial consumption across countries varied from 9.6 DDD in the Netherlands to 28.5 DDD in Greece [25] - The percentage of WHO 'Access' group antibiotics consumed was 61.5% in 2023, which is 0.4 percentage points higher than in 2019 but 3.5 percentage points below the 2030 target of >65% [27] Community Sector Insights - The mean consumption of antibacterials in the community sector was 18.3 DDD per 1,000 inhabitants per day in 2023, with no statistically significant trend detected between 2019 and 2023 [25] - The most consumed subgroup of antibiotics in the community was penicillins (47%), followed by macrolides, lincosamides, and streptogramins (17%) [25] Hospital Sector Insights - In the hospital sector, the mean consumption of antibacterials was 1.6 DDD per 1,000 inhabitants per day in 2023, with no significant trend detected [25] - The proportion of 'broad-spectrum' antibiotics in the hospital sector was 40.1% in 2023, with no significant trend observed during the period [3] Progress Towards EU Targets - The EU aims to reduce total antibiotic consumption by 20% by 2030 compared to 2019 levels, targeting a reduction from 19.9 DDD to 15.9 DDD per 1,000 inhabitants per day [18] - Individual Member States have recommended reductions ranging from 3% to 27% based on their baseline consumption [18] Data Collection and Methodology - The report is based on data from 27 countries, including 25 EU Member States and two EEA countries, with data primarily sourced from sales and reimbursement reports [20][6] - The methodology employs the WHO ATC/DDD classification to standardize antimicrobial consumption metrics [6][8]